相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis
Stephanie L. Swift et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)
Comprehensive Evaluation of the Factors Affecting Plasma Circulating Cell-Free DNA Levels and Their Application in Diagnosing Nonsmall Cell Lung Cancer
Zhiyao Chen et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2019)
Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer
Sandra Liebs et al.
CANCER MEDICINE (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Circulating tumor DNA detection: A potential tool for colorectal cancer management
Huizi Li et al.
ONCOLOGY LETTERS (2019)
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
S. Valpione et al.
EUROPEAN JOURNAL OF CANCER (2018)
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Francesco Sclafani et al.
SCIENTIFIC REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
A. K. Boysen et al.
CLINICA CHIMICA ACTA (2018)
Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy
Kerstin Zwirner et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review
Veronika Vymetalkova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation
Huiyi Liang et al.
NATURE COMMUNICATIONS (2018)
Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer
Morten Lapin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results
J. Kevin Hicks et al.
LUNG CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Origins, structures, and functions of circulating DNA in oncology
A. R. Thierry et al.
CANCER AND METASTASIS REVIEWS (2016)
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Safia El Messaoudi et al.
CLINICAL CANCER RESEARCH (2016)
Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay
Roza Bidshahri et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases
Nick Beije et al.
MOLECULAR ONCOLOGY (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
Feifei Cheng et al.
ONCOTARGET (2016)
Controls to validate plasma samples for cell free DNA quantification
Niels Pallisgaard et al.
CLINICA CHIMICA ACTA (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation
Bo Zhang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2015)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Circulating Cell-Free DNA An Up-Coming Molecular Marker in Exercise Physiology
Sarah Breitbach et al.
SPORTS MEDICINE (2012)
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer
Jorja D. Warren et al.
BMC MEDICINE (2011)
Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer
Alenka Licar et al.
MEDICAL ONCOLOGY (2011)
Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer
Benoit Lefebure et al.
ANNALS OF SURGERY (2010)
Overview of circulating nucleic acids in plasma/serum
Asif N. Butt et al.
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
Philip D. Bonomi et al.
CLINICAL CANCER RESEARCH (2007)
Molecular genetics of pancreatic intraepithelial neoplasia
Georg Feldmann et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2007)
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features
IYS Tam et al.
CLINICAL CANCER RESEARCH (2006)
Impact of EGFR expression on colorectal cancer patient prognosis and survival
JP Spano et al.
ANNALS OF ONCOLOGY (2005)
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
BM Ryan et al.
GUT (2003)
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis
T Lecomte et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
